StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report released on Saturday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
Shares of TTNP stock opened at $3.98 on Friday. Titan Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $14.80. The business has a fifty day simple moving average of $3.53 and a 200 day simple moving average of $4.36.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- What is a buyback in stocks? A comprehensive guide for investors
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- Want to Profit on the Downtrend? Downtrends, Explained.
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
